Background Background Repetitive transcranial
Repetitive transcranial magnetic stimulation (rTMS) has been magnetic stimulation (rTMS) has been proposed as a new treatment option for proposed as a new treatment option for depression.Previous studies were depression.Previous studies were performed with low sample sizes in single performed with low sample sizes in single centres and reported heterogeneous centres and reported heterogeneous results. results.
Aims Aims To investigate the efficacy of rTMS
To investigate the efficacy of rTMS as augmentative treatment in depression. as augmentative treatment in depression.
Method Method In a randomised, double-
In a randomised, doubleblind, sham-controlled multicentre trial blind, sham-controlled multicentre trial 127 patients with moderate to severe 127 patients with moderate to severe depressive episodes were randomly depressive episodes were randomly assigned to real or sham stimulation for assigned to real or sham stimulation for 3 weeks in addition to simultaneously 3 weeks in addition to simultaneously initiated antidepressant medication. initiated antidepressant medication.
Results
Results We found no difference in the We found no difference in the responder rates of the real and the sham responder rates of the real and the sham treatment groups (31% in each) or in the treatment groups (31% in each) or in the decrease of the scores on the depression decrease of the scores on the depression rating scales. rating scales.
Conclusions Conclusions The data do not support
The data do not support previous reports from smaller samples previous reports from smaller samples indicating an augmenting or accelerating indicating an augmenting or accelerating antidepressant effect of rTMS.Further antidepressant effect of rTMS.Further exploration of the possible efficacy of exploration of the possible efficacy of other stimulation protocols or within other stimulation protocols or within selected sub-populations of patients is selected sub-populations of patients is necessary. necessary.
Declaration of interest
Declaration of interest None.
None.
Major depression is one of the leading Major depression is one of the leading causes of disease burden worldwide (Berton causes of disease burden worldwide (Berton & Nestler, 2006) . Its impact on society & Nestler, 2006) . Its impact on society with respect to human suffering and ecowith respect to human suffering and economic charge is enormous, and is even pronomic charge is enormous, and is even projected to increase in upcoming decades jected to increase in upcoming decades (Lopez & Murray, 1998) . Since the discov- (Lopez & Murray, 1998) . Since the discovery of drugs with antidepressant properties ery of drugs with antidepressant properties in the 1950s, no essentially innovative in the 1950s, no essentially innovative treatment strategy has been established for treatment strategy has been established for routine clinical use. Resistance to the availroutine clinical use. Resistance to the available treatment strategies is encountered in able treatment strategies is encountered in 15-30% of patients. New treatment 15-30% of patients. New treatment approaches are therefore needed. Repetitive approaches are therefore needed. Repetitive transcranial magnetic stimulation (rTMS) transcranial magnetic stimulation (rTMS) was introduced as a promising new treatwas introduced as a promising new treatment option for depression and showed ment option for depression and showed beneficial effects in single-centre studies beneficial effects in single-centre studies (Burt (Burt et al et al, 2002; Kozel & George, 2002; , 2002; Kozel & George, 2002; Loo & Mitchell, 2005) . However, it re- Loo & Mitchell, 2005) . However, it remains difficult to draw general conclusions mains difficult to draw general conclusions about the antidepressant efficacy of rTMS about the antidepressant efficacy of rTMS because of heterogeneous study designs, because of heterogeneous study designs, variable stimulation parameters and low variable stimulation parameters and low sample sizes (Martin sample sizes (Martin et al et al, 2003) . , 2003).
METHOD METHOD Study design and participants Study design and participants
The aim of this multicentre trial was to The aim of this multicentre trial was to evaluate whether the application of rTMS in evaluate whether the application of rTMS in a routine clinical setting as an additional strata routine clinical setting as an additional strategy to standard antidepressant medication egy to standard antidepressant medication would enhance the clinical improvement of would enhance the clinical improvement of depression compared with sham treatment depression compared with sham treatment with regard to the number of responders with regard to the number of responders and the decrease in depression rating scores. and the decrease in depression rating scores. Psychiatric departments in seven university Psychiatric departments in seven university clinics -Munich (Ludwig-Maximilian Uniclinics -Munich (Ludwig-Maximilian University), Regensburg, Rostock, Tubingen, versity), Regensburg, Rostock, Tü bingen, Ulm and Wurzburg in Germany, and Ulm and Wü rzburg in Germany, and Vienna in Austria -with experience in Vienna in Austria -with experience in transcranial magnetic stimulation studies transcranial magnetic stimulation studies participated in this randomised doubleparticipated in this randomised doubleblind placebo-controlled, multicentre trial. blind placebo-controlled, multicentre trial. Randomisation to the real and sham treatRandomisation to the real and sham treatment conditions was performed centrally ment conditions was performed centrally prior to the study by the Institute of Bioprior to the study by the Institute of Biometrics of the University of Ulm. Patients, metrics of the University of Ulm. Patients, raters and medical staff at the in-patient raters and medical staff at the in-patient units were all masked to the treatment conunits were all masked to the treatment conditions. Montgomery & Å sberg, 1979) . The cut-off at 18 points was chosen 1979). The cut-off at 18 points was chosen because in all three scales it is within the because in all three scales it is within the range of the transition from mild range of the transition from mild to medium to medium severity of depression. Exclusion criteria severity of depression. Exclusion criteria were neurological and severe medical were neurological and severe medical disdisorders, psychiatric disorders other than orders, psychiatric disorders other than depression, history of epileptic seizures, depression, history of epileptic seizures, brain lesions or neurosurgery, cardiac pacebrain lesions or neurosurgery, cardiac pacemaker, inability to give informed consent, maker, inability to give informed consent, and involuntary hospitalisation. Included and involuntary hospitalisation. Included patients were given an identification patients were given an identification number linked to a centralised computernumber linked to a centralised computergenerated randomisation code determining generated randomisation code determining real or sham stimulation condition. real or sham stimulation condition. Randomisation was stratified for centre Randomisation was stratified for centre and for HRSD score and for HRSD score 4 430 or 30 or 4 430 at 30 at enrolment. Raters underwent training at enrolment. Raters underwent training at the beginning of the study to increase the beginning of the study to increase interrater reliability. interrater reliability.
The following individual and clinical The following individual and clinical features at baseline were documented (see features at baseline were documented (see Table 1 ): duration of the current episode Table 1) : duration of the current episode before rTMS, number of episodes in the hisbefore rTMS, number of episodes in the history including the current episode (1-3 tory including the current episode (1-3 v.
v. 4 43), treatment resistance (no response to 3), treatment resistance (no response to two different antidepressant medications two different antidepressant medications and one combination treatment with treatand one combination treatment with treatment periods of at least 4 weeks each in ment periods of at least 4 weeks each in sufficient dosage for the current episode), sufficient dosage for the current episode), polarity (depressive episode within unipolar polarity (depressive episode within unipolar or bipolar disorder), a medical record of or bipolar disorder), a medical record of family history for depression, and history family history for depression, and history of a severe psychosocial stressor in the year of a severe psychosocial stressor in the year before manifestation of the current episode before manifestation of the current episode (such as death of a close relative, separation (such as death of a close relative, separation from a partner or loss of work). from a partner or loss of work).
Transcranial magnetic stimulation Transcranial magnetic stimulation
Each clinic used the locally available magEach clinic used the locally available magnetic stimulator with figure-of-eight coils: netic stimulator with figure- A biphasic pulse waveform was sestock. A biphasic pulse waveform was selected for all stimulations. The participant lected for all stimulations. The participant was seated in a comfortable chair during was seated in a comfortable chair during the procedure. The real stimulation was apthe procedure. The real stimulation was applied above the left dorsolateral prefrontal plied above the left dorsolateral prefrontal cortex, targeted by guiding the coil to the cortex, targeted by guiding the coil to the position F3 according to the international position F3 according to the international 10-20 system for electroencephalography 10-20 system for electroencephalography electrode placement (Herwig electrode placement (Herwig et al et al, 2003 (Herwig et al et al, , 2003b . ). The real stimulation intensity was deterThe real stimulation intensity was determined as 110% of the individual resting mined as 110% of the individual resting motor threshold (Rossini motor threshold (Rossini et al et al, 1994) . , 1994). Inter-individual differences in cortical Inter-individual differences in cortical excitability and the use of different excitability and the use of different stimulators were thereby taken into account. stimulators were thereby taken into account. Stimulations were performed with a freStimulations were performed with a frequency of 10 Hz, trains of 2 s, inter-trainquency of 10 Hz, trains of 2 s, inter-trainintervals of 8 s, 100 trains per session, intervals of 8 s, 100 trains per session, 2000 stimuli per day on 15 subsequent 2000 stimuli per day on 15 subsequent working days. Sham stimulation was apworking days. Sham stimulation was applied 5 cm lateral to F3, perpendicular to plied 5 cm lateral to F3, perpendicular to the parasagittal plane, above the left the parasagittal plane, above the left temporal muscle; in this position the coiltemporal muscle; in this position the coilcortex distance is essentially larger (more cortex distance is essentially larger (more than 3 cm than 3 cm v.
v. 1-1.5 cm) than at F3, and the 1-1.5 cm) than at F3, and the electromagnetic field reaching the cortex electromagnetic field reaching the cortex was therefore substantially weaker. To was therefore substantially weaker. To further reduce the possible effectiveness of further reduce the possible effectiveness of the sham stimulation the coil was angled the sham stimulation the coil was angled at 45 at 458 8, touching the skull not with the cen-, touching the skull not with the centre but with the rim opposite the handle, tre but with the rim opposite the handle, and the stimulation intensity was reduced and the stimulation intensity was reduced to 90% of motor threshold. Although the to 90% of motor threshold. Although the angling of the coil might have been regisangling of the coil might have been registered by the patients as being different from tered by the patients as being different from the coil handling involved in measuring the the coil handling involved in measuring the motor threshold, this was a compromise motor threshold, this was a compromise made in an attempt to make the sham conmade in an attempt to make the sham condition as similar as possible concerning dition as similar as possible concerning side-effects to the real one but with miniside-effects to the real one but with minimum efficacy. Owing to the substantially mum efficacy. 
Concomitant treatments Concomitant treatments
In order to integrate rTMS in a naturalistic In order to integrate rTMS in a naturalistic routine clinical setting, and for ethical and routine clinical setting, and for ethical and safety reasons, rTMS was applied in safety reasons, rTMS was applied in parallel with a standardised antidepressant parallel with a standardised antidepressant medication or as monotherapy when no medication or as monotherapy when no medication was possible. The stimulation medication was possible. The stimulation sessions were started together with a vensessions were started together with a venlafaxine or mirtazapine treatment, both lafaxine or mirtazapine treatment, both selected because of their combined serotoselected because of their combined serotonergic and noradrenergic profile in order nergic and noradrenergic profile in order to rule out neurotransmitter-specific conto rule out neurotransmitter-specific confounding effects. Prior antidepressant medifounding effects. Prior antidepressant medication was washed out (4 cation was washed out (4 t t ½ ½ ). Venlafaxine ). Venlafaxine was started at a dosage of 75 mg per day was started at a dosage of 75 mg per day in the first week, and mirtazapine at a doin the first week, and mirtazapine at a dosage of 15 mg per day. Both treatments sage of 15 mg per day. Both treatments could be increased later according to clinicould be increased later according to clinical need as evaluated by the responsible cal need as evaluated by the responsible psychiatrist. No other antidepressant or psychiatrist. No other antidepressant or concomitant antipsychotic medication was concomitant antipsychotic medication was allowed. A maximum of 1.5 mg lorazepam allowed. A maximum of 1.5 mg lorazepam per day was permitted as crisis medication. per day was permitted as crisis medication. Patients whose condition had been stable Patients whose condition had been stable on lithium treatment for at least 3 months on lithium treatment for at least 3 months before starting rTMS were allowed to before starting rTMS were allowed to continue taking this medication. Anticontinue taking this medication. Anticonvulsants were not allowed. Nonconvulsants were not allowed. Nonpsychiatric medication was continued as psychiatric medication was continued as needed and documented. All other treatneeded and documented. All other treatments, such as psychotherapy and supments, such as psychotherapy and supportive therapies (music, occupational portive therapies (music, occupational therapy, etc.), were also continued and therapy, etc.), were also continued and documented, and compared between the documented, and compared between the real and the sham stimulation group. real and the sham stimulation group. The primary objective was to demonThe primary objective was to demonstrate that rTMS adjunctive to standard strate that rTMS adjunctive to standard antidepressant treatment results in a greater antidepressant treatment results in a greater number of responders (defined as patients number of responders (defined as patients with an improvement in scores on at least with an improvement in scores on at least two of the three rating scales by at least two of the three rating scales by at least 50% after 3 weeks of rTMS) than sham 50% after 3 weeks of rTMS) than sham treatment (primary hypothesis). The sectreatment (primary hypothesis). The secondary objective was to show a greater ondary objective was to show a greater decrease in the depression rating scores decrease in the depression rating scores with real rTMS than by sham treatment with real rTMS than by sham treatment (secondary hypothesis). Remission was de-(secondary hypothesis). Remission was defined descriptively as a score of 10 points fined descriptively as a score of 10 points or below in all three scales. The BDI, or below in all three scales. The BDI, HRSD and MADRS rating scales were HRSD and MADRS rating scales were administered prior to the stimulation administered prior to the stimulation sessions (rating 1); after 1 week and 2 sessions (rating 1); after 1 week and 2 weeks (ratings 2 and 3); at the end of the weeks (ratings 2 and 3); at the end of the stimulation series after 3 weeks (rating 4); stimulation series after 3 weeks (rating 4); and at a follow-up interview 3 weeks later and at a follow-up interview 3 weeks later (rating 5). The first rating was made on (rating 5). The first rating was made on the day before the stimulation period comthe day before the stimulation period commenced. If rTMS was started the day after menced. If rTMS was started the day after recruitment, the recruitment ratings were recruitment, the recruitment ratings were considered instead. considered instead.
Efficacy variables and statistical
On the basis of previous reports (e.g. ) and presuming a clinically meaningful response in the real treatment group, we ful response in the real treatment group, we assumed a response rate of 50% due to augassumed a response rate of 50% due to augmentative and accelerative effects of rTMS mentative and accelerative effects of rTMS after 3 weeks of stimulation compared with after 3 weeks of stimulation compared with a sham response rate of 20% with the rea sham response rate of 20% with the response due to medication assumed to occur sponse due to medication assumed to occur later. Accordingly, the calculation of the later. Accordingly, the calculation of the sample size indicated that 45 patients were sample size indicated that 45 patients were needed in each group to detect a difference needed in each group to detect a difference in response rates between groups with in response rates between groups with 80% power at a 5% significance level. 80% power at a 5% significance level. Presuming an estimated withdrawal rate Presuming an estimated withdrawal rate of 20%, we aimed to include 120 patients of 20%, we aimed to include 120 patients in the study. in the study.
The primary efficacy variable analysed The primary efficacy variable analysed in the intention-to-treat set was treatment in the intention-to-treat set was treatment response. The comparison between treatresponse. The comparison between treatment groups was performed by means of ment groups was performed by means of a Wald chi-squared test in a logistic rea Wald chi-squared test in a logistic regression model for the primary efficacy gression model for the primary efficacy variable, adjusting for the stratification variable, adjusting for the stratification variables 'centre' (the centres Munich, variables 'centre' (the centres Munich, Regensburg and Vienna, which had a joint Regensburg and Vienna, which had a joint rTMS training, were pooled in order to rTMS training, were pooled in order to avoid numerical problems due to too small avoid numerical problems due to too small sample sizes), and 'HRSD' (score sample sizes), and 'HRSD' (score 4 430 30 v. v. 4 430). Treatment 30). Treatment 6 6 centre and treatment centre and treatment 6 6 HRSD interactions were tested in the HRSD interactions were tested in the model but were eliminated because model but were eliminated because P P values values exceeded 0.05. Results are described using exceeded 0.05. Results are described using odds ratios, 95% confidence intervals and odds ratios, 95% confidence intervals and P P values. Secondary efficacy variables were values. Secondary efficacy variables were the absolute and relative changes from the absolute and relative changes from rating 1 to 4 and 5 (before and after 3 rating 1 to 4 and 5 (before and after 3 weeks of stimulation, and at the followweeks of stimulation, and at the followup) in the depression scores on HRSD, up) in the depression scores on HRSD, MADRS and BDI. They were compared be-MADRS and BDI. They were compared between treatment groups using an tween treatment groups using an F F-test in a -test in a three-way analysis of variance (ANOVA) three-way analysis of variance (ANOVA) with treatment, centre and HRSD score as with treatment, centre and HRSD score as the main effects. Treatment the main effects. Treatment 6 6 centre and centre and treatment treatment 6 6 HRSD interactions were again HRSD interactions were again tested, and eliminated as tested, and eliminated as P P values were values were greater than 0.05. Least square means with greater than 0.05. Least square means with 95% confidence intervals and 95% confidence intervals and P P values values for the comparisons between groups are for the comparisons between groups are reported. reported.
Additional explorative analyses assesAdditional explorative analyses assessing the interaction effect of age ( sing the interaction effect of age (4 460 years 60 years v. v. 4 460 years), gender, device type and 60 years), gender, device type and concomitant medication with treatment on concomitant medication with treatment on the primary end-point were performed, by the primary end-point were performed, by also including age or gender respectively also including age or gender respectively in the models used for efficacy analyses. in the models used for efficacy analyses. Owing to associations between device type Owing to associations between device type and centre, device type was used instead of and centre, device type was used instead of centre in the respective models. centre in the respective models.
All statistical analyses were performed All statistical analyses were performed with the Statistical Analysis System softwith the Statistical Analysis System software package, version 8.02 for Windows. ware package, version 8.02 for Windows.
RESULTS RESULTS

Participants Participants
The intention-to-treat (ITT) sample comThe intention-to-treat (ITT) sample comprised 127 patients (Fig. 1, Table 1 ). The prised 127 patients (Fig. 1 Of the 127 patients, 62 were randomised to the real stimulation group randomised to the real stimulation group and 65 to the sham group. In the period and 65 to the sham group. In the period between enrolment and start of the treatbetween enrolment and start of the treatment, 5 patients showed an improvement ment, 5 patients showed an improvement in their depressive symptoms such that they in their depressive symptoms such that they no longer fulfilled the inclusion criteria. no longer fulfilled the inclusion criteria. Two patients had to be excluded during Two patients had to be excluded during or after stimulation (1 because of psychotic or after stimulation (1 because of psychotic symptoms and 1 because a data review symptoms and 1 because a data review revealed an erroneous inclusion) and were revealed an erroneous inclusion) and were not considered for the per protocol analysis. not considered for the per protocol analysis. Fifteen participants withdrew during the Fifteen participants withdrew during the stimulation series, 6 from the real intervenstimulation series, 6 from the real intervention group and 9 from the sham group, for tion group and 9 from the sham group, for the reasons detailed in Fig. 1 . Thus, 105 the reasons detailed in Fig. 1 . Thus, 105 patients received stimulation according to patients received stimulation according to protocol over the whole period of 3 weeks: protocol over the whole period of 3 weeks: 52 with real stimulation and 53 with the 52 with real stimulation and 53 with the sham condition. Follow-up ratings 3 weeks sham condition. Follow-up ratings 3 weeks after the end of the stimulation sessions after the end of the stimulation sessions were performed in 50 participants in the were performed in 50 participants in the real group and 48 in the sham group; the real group and 48 in the sham group; the remaining patients refused to participate remaining patients refused to participate or could not be contacted. Administration or could not be contacted. Administration of concomitant medication was similar in of concomitant medication was similar in both groups, including mean dosages both groups, including mean dosages (Table 1) . Treatment groups were similar (Table 1) . Treatment groups were similar with respect to a continuation of supportive with respect to a continuation of supportive treatments such as occupational therapy, treatments such as occupational therapy, music therapy, relaxation techniques, supmusic therapy, relaxation techniques, supportive psychotherapy (real, portive psychotherapy (real, n n¼52; sham, 52; sham, n n¼49) and, if established, a continuation 49) and, if established, a continuation of cognitive-behavioural or interpersonal of cognitive-behavioural or interpersonal therapy (real, therapy (real, n n¼19; sham, 19; sham, n n¼20). In the 20). In the frame of the multiple comparisons of the frame of the multiple comparisons of the baseline characteristics we found the real baseline characteristics we found the real 4 4 3 4 4 3 AUTHOR'S PROOF AUTHOR'S PROOF CONSORT flowchart (rTMS, repetitive transcranial magnetic stimulation).
group to include more women than the group to include more women than the sham group and to score marginally higher sham group and to score marginally higher on the HRSD in the ITT set (no difference on the HRSD in the ITT set (no difference in an additional testing of the PP set: in an additional testing of the PP set: P P¼0.08), but not on the BDI or the 0.08), but not on the BDI or the MADRS. The other features and clinical MADRS. The other features and clinical baseline characteristics were similar in the baseline characteristics were similar in the two groups (Table 1) . two groups (Table 1) .
Primary and secondary efficacy Primary and secondary efficacy outcome outcome v. 33 33 non-responders (53%) and 33 non-responnon-responders (53%) and 33 non-responders (51%) respectively. The remaining ders (51%) respectively. The remaining patients withdrew from the trial or were patients withdrew from the trial or were excluded (real, excluded (real, n n¼10, 16%; sham, 10, 16%; sham, n n¼12, 12, 18%; Fig. 1 ). For the ITT analysis of 18%; Fig. 1 ). For the ITT analysis of primary efficacy, missing values for the primary efficacy, missing values for the patients who withdrew were recorded as patients who withdrew were recorded as non-response. After adjusting for centre non-response. After adjusting for centre and HRSD score at the start of the study, and HRSD score at the start of the study, there was no significant difference in rethere was no significant difference in responder rates between the different groups sponder rates between the different groups (OR (OR¼1.0, 95% CI 0.5-2.2, Wald 1.0, 95% CI 0.5-2.2, Wald w w 2 2 test, test, P P¼0.962; Table 2 ). There was no meaning-0.962; Table 2 ). There was no meaningful difference in the response rates between ful difference in the response rates between the centres ( the centres (P P¼0.339). 0.339).
The ANOVA of the secondary efficacy The ANOVA of the secondary efficacy variables, i.e. the absolute and relative variables, i.e. the absolute and relative changes from rating 1 to rating 4 (end of changes from rating 1 to rating 4 (end of the rTMS period; Table 2, Fig. 2 ) and the rTMS period; Table 2, Fig. 2 ) and rating 5 (follow-up) of the depression rating 5 (follow-up) of the depression scores on the HRSD, MADRS and BDI, scores on the HRSD, MADRS and BDI, revealed no difference between the real revealed no difference between the real and sham groups at the end of the stimulaand sham groups at the end of the stimulation sessions. In the per protocol data-set, tion sessions. In the per protocol data-set, logistic regression showed no difference in logistic regression showed no difference in the responder rates between the real and the responder rates between the real and sham stimulation groups at any point sham stimulation groups at any point during the course of stimulation, and thus during the course of stimulation, and thus no accelerated antidepressant effect (Fig.  no accelerated antidepressant effect (Fig.  3) . Further, there was no meaningful differ-3). Further, there was no meaningful difference in the responder rates between the ence in the responder rates between the treatment groups after the follow-up period treatment groups after the follow-up period (Wald (Wald w w 2 2 test, test, P P¼0.34). With regard to the 0.34). With regard to the absolute and relative changes in the rating absolute and relative changes in the rating scores, no meaningful difference was obscores, no meaningful difference was observed between the real and sham stimulaserved between the real and sham stimulation groups in the ratings after 1 week, tion groups in the ratings after 1 week, after 2 weeks and at follow-up (Fig. 4) . Reafter 2 weeks and at follow-up (Fig. 4) . Remission of depression was found in 6 peomission of depression was found in 6 people in the real group and 10 people in the ple in the real group and 10 people in the sham group. sham group.
Explorative analyses did not show any Explorative analyses did not show any meaningful interaction effect of age, genmeaningful interaction effect of age, gender, device type or concomitant medication der, device type or concomitant medication with treatment on the primary efficacy with treatment on the primary efficacy outcome. outcome.
Side-effects Side-effects
Patients complained of the following sidePatients complained of the following sideeffects related to rTMS: headache (real, effects related to rTMS: headache (real, n n¼3; sham, 3; sham, n n¼1), dizziness (real, 1), dizziness (real, n n¼0; 0; sham, sham, n n¼1) painful local sensation (real, 1) painful local sensation (real, n n¼1; sham, 1; sham, n n¼2) and nausea (real, 2) and nausea (real, n n¼1; 1; sham, sham, n n¼0). Most patients reported that 0). Most patients reported that the stimulation generally caused an the stimulation generally caused an uncomfortable local sensation but they did uncomfortable local sensation but they did 4 4 4 4 4 4 AUTHOR'S PROOF AUTHOR'S PROOF not complain about this as a side-effect. We not complain about this as a side-effect. We observed no epileptic seizure or other observed no epileptic seizure or other severe side-effect. severe side-effect.
DISCUSSION DISCUSSION
The aim of this multicentre trial was to The aim of this multicentre trial was to investigate the antidepressant effect of investigate the antidepressant effect of rTMS as an augmentative and/or accelerarTMS as an augmentative and/or accelerative treatment to simultaneously initiated tive treatment to simultaneously initiated antidepressant medication in a routine antidepressant medication in a routine clinical setting. We did not find beneficial clinical setting. We did not find beneficial effects of active rTMS compared with the effects of active rTMS compared with the sham condition with regard to responder sham condition with regard to responder rates or changes in the rating scores. rates or changes in the rating scores. Furthermore, no acceleration of a clinical Furthermore, no acceleration of a clinical improvement was observed. No severe sideimprovement was observed. No severe sideeffect such as epileptic seizure occurred, effect such as epileptic seizure occurred, indicating that the method may be considindicating that the method may be considered to be safe within the frame of our ered to be safe within the frame of our study design and as far as the limits of study design and as far as the limits of our sample size allow. our sample size allow. Transcranial magnetic stimulation deTranscranial magnetic stimulation depolarises neurons in targeted cortex areas polarises neurons in targeted cortex areas focally and non-invasively through inducfocally and non-invasively through induction of a transient electromagnetic field that tion of a transient electromagnetic field that is generated by a pulsed electrical current is generated by a pulsed electrical current running through a wound copper coil. The running through a wound copper coil. The induction of local and trans-synaptically induction of local and trans-synaptically mediated metabolic and biochemical changes mediated metabolic and biochemical changes in pathophysiologically relevant brain areas in pathophysiologically relevant brain areas was suggested as a rationale for an antidewas suggested as a rationale for an antidepressant effect (Post & Keck, 2001 ). The pressant effect (Post & Keck, 2001) . The left dorsolateral prefrontal cortex was left dorsolateral prefrontal cortex was selected as a main target area for stimulaselected as a main target area for stimulation in patients with depression on the basis tion in patients with depression on the basis of imaging studies that attributed of imaging studies that attributed depressive symptoms to a regional hypomedepressive symptoms to a regional hypometabolism which might be upregulated by tabolism which might be upregulated by rTMS (Pascual-Leone rTMS (Pascual- Leone et al et al, 1996) . The , 1996) . The antidepressant properties of rTMS have antidepressant properties of rTMS have now been investigated for more than 10 now been investigated for more than 10 years, and initial positive studies elicited years, and initial positive studies elicited hope in both the scientific community and hope in both the scientific community and the public. Presumably in routine clinical the public. Presumably in routine clinical care rTMS would be mainly applied concocare rTMS would be mainly applied concomitantly with other antidepressant treatmitantly with other antidepressant treatments; for this reason an additional ments; for this reason an additional benefit of rTMS should be demonstrated benefit of rTMS should be demonstrated in controlled clinical trials. in controlled clinical trials. results require discussion in more detail in results require discussion in more detail in relation to our results. In a trial investigatrelation to our results. In a trial investigating rTMS (5 Hz, 120% of motor threshold, ing rTMS (5 Hz, 120% of motor threshold, 1200 stimuli per day) above the left dorso-1200 stimuli per day) above the left dorsolateral prefrontal cortex, given in parallel lateral prefrontal cortex, given in parallel with amitriptyline titrated up to a therapeuwith amitriptyline titrated up to a therapeutic dosage during the week before starting tic dosage during the week before starting rTMS, beneficial effects were found already rTMS, beneficial effects were found already after the first week of stimulation and were after the first week of stimulation and were sustained for the stimulation period of 4 sustained for the stimulation period of 4 weeks (Rumi weeks (Rumi et al et al, 2005) . Another study, , 2005). Another study, combining rTMS (15 Hz, 100% of motor combining rTMS (15 Hz, 100% of motor threshold, 900 stimuli per day) above the threshold, 900 stimuli per day) above the left dorsolateral prefrontal cortex with left dorsolateral prefrontal cortex with venlafaxine, citalopram or sertraline started venlafaxine, citalopram or sertraline started simultaneously and titrated up quickly, simultaneously and titrated up quickly, found beneficial effects after 2 weeks of found beneficial effects after 2 weeks of stimulation, but these benefits had disstimulation, but these benefits had disappeared at the follow-up assessment 3 appeared at the follow-up assessment 3 weeks later (Rossini weeks later (Rossini et al et al, 2005) . Concern-, 2005) . Concerning stimulation parameters, the values used ing stimulation parameters, the values used in our study (10 Hz, 110% motor threshin our study (10 Hz, 110% motor threshold) were between those of the two studies old) were between those of the two studies mentioned above but our daily amount of mentioned above but our daily amount of stimuli was higher, so that these differences stimuli was higher, so that these differences can hardly account for our negative results. can hardly account for our negative results. A further study reporting beneficial effects A further study reporting beneficial effects (Anderson (Anderson et al et al, 2007) applied rTMS at , 2007) applied rTMS at 10 Hz, 110% of motor threshold, 1000 sti-10 Hz, 110% of motor threshold, 1000 stimuli per day, three times per week for 4-6 muli per day, three times per week for 4-6 weeks while the patients were maintained weeks while the patients were maintained on established medication. Here, the differon established medication. Here, the difference from our results might be due to unence from our results might be due to unchanged medication in largely treatmentchanged medication in largely treatmentresistant patients, with thus no further resistant patients, with thus no further medication effect as indicated by a low remedication effect as indicated by a low response in the sham group (7%), and to sponse in the sham group (7%), and to the longer stimulation period. Generally, the longer stimulation period. Generally, different regimens of co-medication in these different regimens of co-medication in these studies are to be considered when comparstudies are to be considered when comparing the results. Other add-on rTMS studies ing the results. Other add-on rTMS studies with negative results might have suffered with negative results might have suffered from insufficient stimulation parameters from insufficient stimulation parameters such as sub-threshold intensity and low such as sub-threshold intensity and low number of stimuli (Poulet number of stimuli (Poulet et al et al, 2004) . , 2004). The stimulation parameters for our The stimulation parameters for our study were chosen as those most likely to study were chosen as those most likely to have a possible antidepressant effect, based have a possible antidepressant effect, based on the evidence available at the time of on the evidence available at the time of study conception: higher intensities study conception: higher intensities ( (5 5100% of motor threshold), frequencies 100% of motor threshold), frequencies ( (5 55 Hz) and total amounts of stimuli 5 Hz) and total amounts of stimuli ( (5 510 000); treatment periods of at least 10 000); treatment periods of at least 10 days; and targeting the left dorsolateral 10 days; and targeting the left dorsolateral prefrontal cortex (e.g. Pascual . One might argue that our chosen stimulation period of 3 that our chosen stimulation period of 3 weeks was too short. However, the aboveweeks was too short. However, the abovementioned papers and the majority of other mentioned papers and the majority of other relevant studies reported positive effects relevant studies reported positive effects even earlier, i.e. after 1-2 weeks of stimulaeven earlier, i.e. after 1-2 weeks of stimulation. A single-centre study that used the tion. A single-centre study that used the same parameters concerning intensity, same parameters concerning intensity, frequency, location and duration as we did, frequency, location and duration as we did, albeit with fewer stimuli per day (1600) in albeit with fewer stimuli per day (1600) in 5 s trains and with a different study design, 5 s trains and with a different study design, recently reported beneficial rTMS effects in recently reported beneficial rTMS effects in treatment-resistant depression (Avery treatment-resistant depression (Avery et al et al, , 2006) . Thus, on the basis of the literature, 2006). Thus, on the basis of the literature, we could have expected to detect an antiwe could have expected to detect an antidepressant effect from the stimulation paradepressant effect from the stimulation parameters used in our trial. The improvement meters used in our trial. The improvement observed in both groups of our study may observed in both groups of our study may be explained as an effect of medication, a be explained as an effect of medication, a general placebo effect or the spontaneous general placebo effect or the spontaneous course of the disease. Further, clinical course of the disease. Further, clinical factors such as short episode duration and factors such as short episode duration and lack of treatment resistance, whenever we lack of treatment resistance, whenever we had a strict definition, in some of our had a strict definition, in some of our patients might have accounted for the patients might have accounted for the generally good antidepressant response. generally good antidepressant response. Accordingly, one may argue that a possible Accordingly, one may argue that a possible antidepressant effect of rTMS might have antidepressant effect of rTMS might have been hidden by the medication effect and been hidden by the medication effect and by these clinical factors; but one can at least by these clinical factors; but one can at least state that no beneficial effect of rTMS in state that no beneficial effect of rTMS in addition to newly initiated medication with addition to newly initiated medication with mirtazapine or venlafaxine at the standard mirtazapine or venlafaxine at the standard lower dose range was observed. In this conlower dose range was observed. In this context, it may also be argued that our study text, it may also be argued that our study might have been underpowered and that might have been underpowered and that more patients should have been included more patients should have been included in order to reveal a significant difference. in order to reveal a significant difference. However, we observed the same rates of However, we observed the same rates of responders (31%) in both groups, implying responders (31%) in both groups, implying that even if many more patients had been that even if many more patients had been treated the outcome in the primary efficacy treated the outcome in the primary efficacy variable would not have been any different. variable would not have been any different. As concerns the number of included As concerns the number of included patients, it should be noted that this study patients, it should be noted that this study is one of the largest of rTMS in depression is one of the largest of rTMS in depression reported to date. The antidepressant rereported to date. The antidepressant response found in our study for both stimulasponse found in our study for both stimulation conditions is comparable with the tion conditions is comparable with the results reported for a 3-week period of results reported for a 3-week period of treatment (within longer courses) in treatment (within longer courses) in pharmacological studies that investigated pharmacological studies that investigated the antidepressant response on mirtazapine the antidepressant response on mirtazapine and venlafaxine in terms of changes in and venlafaxine in terms of changes in HRSD and/or MADRS rating scores and re-HRSD and/or MADRS rating scores and response rate (e.g. Amini sponse rate (e.g. Amini et al et al, 2005; Shelton , 2005; Shelton et al et al, 2006) . Accordingly, we found no , 2006). Accordingly, we found no evidence that the response to rTMS and evidence that the response to rTMS and medication in our study was superior to medication in our study was superior to that reported by studies that investigated that reported by studies that investigated solely medication effects. Concerning pasolely medication effects. Concerning patient characteristics, we found no influence tient characteristics, we found no influence of age and gender on outcome. Although of age and gender on outcome. Although other studies suggested an age-dependent other studies suggested an age-dependent rTMS effect with less efficacy in the elderly rTMS effect with less efficacy in the elderly (Mosimann (Mosimann et al et al, 2004; however, that study , 2004;  however, that study used lower intense stimulation parameters), used lower intense stimulation parameters), in our study neither the younger nor the in our study neither the younger nor the older patients responded to rTMS. Further, older patients responded to rTMS. Further, considering our gender distribution, gender considering our gender distribution, gender showed no effect on treatment outcome in showed no effect on treatment outcome in the explorative analysis, which also would the explorative analysis, which also would not have been supported by any evidence not have been supported by any evidence in the literature. The HRSD baseline scores in the literature. The HRSD baseline scores were slightly higher in the real stimulation were slightly higher in the real stimulation group, whereas MADRS and BDI scores group, whereas MADRS and BDI scores did not show any difference between the did not show any difference between the groups. Within a set of multiple comparigroups. Within a set of multiple comparisons it was likely that differences would sons it was likely that differences would be observed in relation to distinct features. be observed in relation to distinct features. The mean absolute difference in HRSD The mean absolute difference in HRSD scores, however, was less than 2 points scores, however, was less than 2 points and therefore clinically marginal. Further, and therefore clinically marginal. Further, the analyses had been adjusted for HRSD the analyses had been adjusted for HRSD score ( score (4 430 30 v.
Comparison with other rTMS
v. 4 430) at the start of the 30) at the start of the study, and no different outcome dependent study, and no different outcome dependent on HRSD score was observed. Considering on HRSD score was observed. Considering these facts and that the study outcome was these facts and that the study outcome was negative, there was no meaningful bias negative, there was no meaningful bias in our view. We further found no inin our view. We further found no influence of stimulator type or concomifluence of stimulator type or concomitant medication on treatment outcome, tant medication on treatment outcome, and no difference in the clinical baseline and no difference in the clinical baseline variables. variables.
Meta-analyses addressing rTMS studies Meta-analyses addressing rTMS studies in depression draw critical conclusions conin depression draw critical conclusions concerning the applied methodology and the cerning the applied methodology and the clinical significance of the results. Kozel clinical significance of the results. Kozel & George (2002) found a mean difference & George (2002) found a mean difference in improvement in studies using real in improvement in studies using real v.
v. sham rTMS of 3 points on the HRSD, the sham rTMS of 3 points on the HRSD, the clinical impact of which appeared to be clinical impact of which appeared to be marginal. Furthermore, for methodological marginal. Furthermore, for methodological reasons they considered only a small numreasons they considered only a small number of the studies on this topic. Martin ber of the studies on this topic. Martin et et al al (2003) also criticised methodological (2003) also criticised methodological issues and concluded that there was no issues and concluded that there was no strong evidence of benefit from using rTMS strong evidence of benefit from using rTMS to treat depression, although the small to treat depression, although the small sample sizes of the studies did not allow sample sizes of the studies did not allow the possibility of such an effect being exthe possibility of such an effect being excluded. A recent meta-analysis concluded cluded. A recent meta-analysis concluded that rTMS may not differ from sham treatthat rTMS may not differ from sham treatment in major depression (Couturier, ment in major depression (Couturier, 2005) . However, that analysis also ex-2005). However, that analysis also excluded several studies because of methodcluded several studies because of methodological issues and therefore based its ological issues and therefore based its outcome on only a few studies. Therefore, outcome on only a few studies. Therefore, the current literature and our data dampen the current literature and our data dampen early expectations about positive effects of early expectations about positive effects of rTMS on depression and indicate that one rTMS on depression and indicate that one should be careful about generally impleshould be careful about generally implementing rTMS in clinical practice. menting rTMS in clinical practice.
Future directions Future directions
Despite this critical report showing no augDespite this critical report showing no augmentative or accelerating antidepressant mentative or accelerating antidepressant properties of rTMS, previous positive reproperties of rTMS, previous positive reports still provide strong arguments for ports still provide strong arguments for the possibility of rTMS providing an antithe possibility of rTMS providing an antidepressant effect under certain circumdepressant effect under certain circumstances. In particular, the possibility of stances. In particular, the possibility of beneficial rTMS effects in selected subbeneficial rTMS effects in selected subpopulations of patients with distinct clinical populations of patients with distinct clinical variables and aetiological or psychopathovariables and aetiological or psychopathological aspects in the sense of certain endological aspects in the sense of certain endophenotypes should be addressed. Also, phenotypes should be addressed. Also, rTMS may be advantageous for patients rTMS may be advantageous for patients with treatment-resistant depression (Avery with treatment-resistant depression (Avery et al et al, 2006; Fitzgerald , 2006; Fitzgerald et al et al, 2006 ). This , 2006 . This issue has been addressed in another multiissue has been addressed in another multicentre trial not published at the time of centre trial not published at the time of the final submission of this manuscript. the final submission of this manuscript. Further, the identification of more specific Further, the identification of more specific and neurobiologically based stimulation and neurobiologically based stimulation parameters, including alternative stimulaparameters, including alternative stimulation sites, may offer new approaches to tion sites, may offer new approaches to finding an antidepressant rTMS effect. finding an antidepressant rTMS effect. Notably, in the light of the diverse neuroNotably, in the light of the diverse neurobiological effects of rTMS (e.g. Post & biological effects of rTMS (e.g. Post & Keck, 2001; Pogarell Keck, 2001; Pogarell et al et al, 2006) , the speci-, 2006), the specific neurobiological basis for a possible fic neurobiological basis for a possible treatment effect and for distinct stimulation treatment effect and for distinct stimulation parameters remains unclear in transcranial parameters remains unclear in transcranial magnetic stimulation research. magnetic stimulation research.
To conclude, this first multicentre trial To conclude, this first multicentre trial investigating rTMS over the left dorsolatinvestigating rTMS over the left dorsolateral prefrontal cortex in depression in a eral prefrontal cortex in depression in a routine clinical setting does not support routine clinical setting does not support the hypothesis of an augmentative or accelthe hypothesis of an augmentative or accelerative antidepressant effect of rTMS in erative antidepressant effect of rTMS in patients with concomitant antidepressant patients with concomitant antidepressant medication. Major tasks for future research medication. Major tasks for future research in this field will be to investigate whether in this field will be to investigate whether patients with distinct subtypes of deprespatients with distinct subtypes of depression would respond preferentially, to idension would respond preferentially, to identify which stimulation parameters might tify which stimulation parameters might be most effective and to further reveal the be most effective and to further reveal the neurobiological background. Given the neurobiological background. Given the heterogeneous nature of reports of this heterogeneous nature of reports of this technique to date, it is recommended that technique to date, it is recommended that the application of rTMS should be rethe application of rTMS should be restricted to the scientific context for further stricted to the scientific context for further exploration of its possible benefits. exploration of its possible benefits. Add-on rTMS for treatment of depression: a pilot study Add-on rTMS for treatment of depression: a pilot study using stereotaxic coil-navigation according to PET data. using stereotaxic coil-navigation according to PET data. 
